HC Wainwright reiterated their buy rating on shares of enGene (NASDAQ:ENGN – Free Report) in a report issued on Tuesday,Benzinga reports. HC Wainwright currently has a $4.00 target price on the stock. Several other research firms have also recently issued reports on ENGN. Morgan Stanley cut enGene from an “equal weight” rating to an “underweight” […]

Immunic (NASDAQ:IMUX – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research note issued to investors on Thursday, Benzinga reports. They currently have a $22.00 price target on the stock. HC Wainwright’s price objective would indicate a potential upside of 80.48% from the stock’s previous close. IMUX […]

HC Wainwright reiterated their buy rating on shares of NewAmsterdam Pharma (NASDAQ:NAMS – Free Report) in a research note issued to investors on Tuesday morning,Benzinga reports. They currently have a $52.00 target price on the stock. NAMS has been the topic of several other reports. Royal Bank Of Canada lowered their target price on shares […]

HC Wainwright reissued their buy rating on shares of Generate Biomedicines (NASDAQ:GENB – Free Report) in a research note published on Tuesday,Benzinga reports. The firm currently has a $30.00 price objective on the stock. A number of other research analysts have also recently issued reports on the stock. Wall Street Zen upgraded shares of Generate […]